Inari Medical, Inc.: directors' dealings · United States · SEC (Form 4)

About Inari Medical, Inc.

Inari Medical, Inc. is a US-based medical device company focused on the interventional treatment of venous and arterial thrombotic disease. Founded in 2011 as a spin-out linked to Inceptus Medical, the company built a differentiated portfolio of purpose-built mechanical thrombectomy systems designed to remove large clot burdens from the vascular system. Its headquarters are in Irvine, California, United States. Inari was listed on the NASDAQ under the ticker NARI before being acquired by Stryker, with the transaction completed on February 19, 2025; that historical market status remains relevant for investors reviewing SEC Form 4 insider activity and the company’s prior public-market disclosures. The company’s business model centered on minimally invasive catheter-based technologies targeting venous thromboembolism and related vascular conditions. Its flagship products include FlowTriever for pulmonary embolism, ClotTriever for deep vein thrombosis, InThrill for smaller venous vessels and dialysis access applications, and Artix for selected arterial thrombectomy use cases. Inari also offers complementary accessories and support systems that help physicians perform procedures efficiently. A key part of the company’s value proposition has been its focus on “lytic-free” or reduced-lytic clot removal, which can lower reliance on thrombolytic drugs and help address the clinical and operational constraints associated with traditional treatment pathways. From a competitive standpoint, Inari established itself as a specialist in peripheral vascular thrombectomy, a niche that sits at the intersection of interventional radiology, vascular surgery, and cardiology. Its competitive edge came from product design, physician education, clinical research, and real-world evidence generation rather than from scale alone. The company built its reputation on solving under-addressed problems in venous disease and on supporting adoption through clinical programs and reimbursement work. Geographically, its core commercial footprint has been the United States, with international expansion efforts that included reimbursement progress in Japan for ClotTriever. Recent developments were dominated by the strategic sale to Stryker, announced in January 2025 and completed in February 2025. Stryker said the acquisition would give it entry into the fast-growing peripheral vascular segment and add Inari’s complementary thrombectomy platform to its broader medical technology portfolio. For investors, the deal marked the transition of Inari from an independent NASDAQ-listed growth medtech company to a subsidiary within a larger global healthcare group, while preserving the significance of its product franchise, clinical data set, and market position in venous thromboembolism.